Boston, MA 02/18/2014 (wallstreetpr) – Staples, Inc. (NASDAQ:SPLS) has issued $7,500 to Massachusetts Foundation for the Humanities through is charitable arm Staples Foundation. The Staple Foundation grant is expected to support Family Adventures in Reading (FAIR). This program presents at 10 public libraries annually around the state and through it professional storytellers treat kids aged up to 10 years to outstanding books and also lead discussions on the stories, more so, how they related to daily life. In the end, the objective is to make the children acquire better communications skills about important issues and this eventually leads to fostering life-long love of reading. Staples, Inc. (NASDAQ:SPLS) lost its market value in the previous session whereby it fall by 0.31 percent to close the day at $13.03.
American Airlines Group Inc (NASDAQ:AAL) Chief Executive Doug Parker realized a profit of $13.4 million after trading shares acquired back in 2008 during which airlines were soaked in trouble because of the high fuel costs. The CEO was among the top executives from US Airways who traded their stake in the new company outfit now that their investment had grown exponentially. Following the latest shares selling, the CEO is now left with about 1.4 million shares whose value is approximately $47 million. US Airways and American Airlines teamed up to form American Airlines Group Inc (NASDAQ:AAL) through a merger deal.
Abbott Laboratories (NYSE:ABT) opened the week on a positive note, gaining 0.23 percent to add 9 cents on each of its shares, thus closing at $38.81 per share. The stock’s price objective was recently lowered to $46 at Jefferies Group. However, the brokerage maintains a “buy” rating on the stock of ABT. The stock is currently tracked by 16 analysts, thus resulting in average price target of $39.42 and consensus rating of “hold.” The company issued its latest quarterly results on January 22, during which it reported earnings per share of 58 cents, thus meeting the Wall Street expectation. Revenue for the quarter was $5.66 billion; however analysts were looking for $5.72 billion. In this case Abbott Laboratories (NYSE:ABT) met EPS expectations but faltered on revenue.
